These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Stereotactic Ablative Radiotherapy for 'Oligometastases': a Treatment in Search of Evidence. Macbeth F; Treasure T Clin Oncol (R Coll Radiol); 2016 Aug; 28(8):501-2. PubMed ID: 26792547 [No Abstract] [Full Text] [Related]
5. Can a FLAME forge a stronger SABRe? Let's await the evidence for focal boost with Stereotactic Ablative Radiotherapy. Correa RJM; Morton G; Loblaw A Radiother Oncol; 2022 Sep; 174():173-174. PubMed ID: 35817321 [No Abstract] [Full Text] [Related]
6. Oligometastases: Incorporate the patient perspective to ensure optimal treatment and care. Buiting HM; van der Linden Y; Steenbruggen TG; Bolt EE; van Houdt W; Sonke GS J Surg Oncol; 2024 Mar; 129(4):679-680. PubMed ID: 38100164 [No Abstract] [Full Text] [Related]
7. Stereotactic ablative radiotherapy in ventricular fibrillation with left ventricular thrombus. Gupta M; Liu E; Shaw G; Oh S; Trombetta M; Sohn J; Thosani AJ HeartRhythm Case Rep; 2023 Dec; 9(12):902-905. PubMed ID: 38204831 [No Abstract] [Full Text] [Related]
8. Evaluation of Clinician Contouring for Pancreatic Stereotactic Ablative Radiotherapy During a Contouring Workshop Organised by the Royal College of Radiologists. Slevin F; Beasley M; Speight R; Lilley J; Murray L; Hawkins M; Radhakrishna G; Henry A Clin Oncol (R Coll Radiol); 2021 Mar; 33(3):e196-e197. PubMed ID: 33129654 [No Abstract] [Full Text] [Related]
9. Response letter by Nassar et al. Nassar AH; Kim SY; Adib E; Naqash AR; Goldberg SB J Thorac Oncol; 2024 May; 19(5):e7-e8. PubMed ID: 38719428 [No Abstract] [Full Text] [Related]
10. Authors' response to Hughes et al. (2024). Pu L; Coppieters MW; Smalbrugge M; Jones C; Byrnes J; Todorovic M; Moyle W J Adv Nurs; 2024 May; ():. PubMed ID: 38738907 [No Abstract] [Full Text] [Related]
11. PulMiCC was Not 'Unsuccessful' and Stereotactic Ablative Body Radiotherapy is Not Like a Parachute: Comments on the Editorial by Ostler et al. Macbeth F Clin Oncol (R Coll Radiol); 2022 Mar; 34(3):e139. PubMed ID: 35042623 [No Abstract] [Full Text] [Related]
12. Stereotactic ablative radiotherapy for pulmonary oligometastases and oligometastatic lung cancer. Shultz DB; Filippi AR; Thariat J; Mornex F; Loo BW; Ricardi U J Thorac Oncol; 2014 Oct; 9(10):1426-33. PubMed ID: 25170641 [TBL] [Abstract][Full Text] [Related]
13. Stereotactic body radiation therapy for oligometastases. Lo SS; Fakiris AJ; Teh BS; Cardenes HR; Henderson MA; Forquer JA; Papiez L; McGarry RC; Wang JZ; Li K; Mayr NA; Timmerman RD Expert Rev Anticancer Ther; 2009 May; 9(5):621-35. PubMed ID: 19445579 [TBL] [Abstract][Full Text] [Related]
14. In Response to: 'Should We be Offering our Patients with Oligometastases Stereotactic Ablative Body Radiotherapy?' by Ostler et al. and 'Should We be Offering our Patients with Oligometastases Stereotactic Ablative Body Radiotherapy - No' by Macbeth and Hughes-Davies. Phillips I; Olson R; Palma D; Harrow S Clin Oncol (R Coll Radiol); 2022 Apr; 34(4):e169-e170. PubMed ID: 35148914 [No Abstract] [Full Text] [Related]
15. Should We be Offering Our Patients With Oligometastases Stereotactic Ablative Body Radiotherapy? Ostler P; Hoskin P; Martin A Clin Oncol (R Coll Radiol); 2021 Dec; 33(12):747-748. PubMed ID: 34642067 [No Abstract] [Full Text] [Related]
16. Should We be Offering our Patients with Oligometastases Stereotactic Ablative Body Radiotherapy - No. Macbeth F; Hughes-Davies L Clin Oncol (R Coll Radiol); 2021 Dec; 33(12):749-750. PubMed ID: 34218999 [No Abstract] [Full Text] [Related]